tiprankstipranks

Amneal Pharmaceuticals announces expanded coverage for Crexont

Amneal Pharmaceuticals (AMRX) announced that three large insurance coverage accounts, the Veterans Administration, UnitedHealthcare (UNH) and CVS Health (CVS), have added Crexont extended-release capsules for the treatment of Parkinson’s disease to their national prescription drug formularies. Crexont is a prescription medication for the treatment of PD approved by the FDA in August 2024. This expanded coverage increases Crexont’s total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50%.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue